Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03500731 · ClinicalTrials.gov registry record · Phase 1
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
A Phase 1 study of Idiopathic Pulmonary Fibrosis and Emphysema or COPD, sponsored by Paul Szabolcs.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 2
- Study locations
NCT03500731 is a Phase 1 study of Idiopathic Pulmonary Fibrosis and Emphysema or COPD that is actively recruiting participants, run by Paul Szabolcs. The registered enrollment target is 8 participants, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03500731, a Phase 1 study of Idiopathic Pulmonary Fibrosis and Emphysema or COPD, is actively recruiting participants, sponsored by Paul Szabolcs.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Alemtuzumab
- DRUG Rituximab
- DRUG Thiotepa
- BIOLOGICAL CD3/CD19 negative hematopoietic stem cells
Study Locations (2)
Pennsylvania
- UPMC Presbyterian - Pittsburgh
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-04-19 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03500731
The ClinicalTrials.gov registry entry for NCT03500731 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (99% lower). The listed sponsor is Paul Szabolcs, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT03500731 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03500731 about?
NCT03500731 is a clinical study titled "Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure". The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.
What is the current status of trial NCT03500731?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-04-19. Estimated completion is 2028-12.
What conditions does trial NCT03500731 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis, Emphysema or COPD.
What interventions are being tested in trial NCT03500731?
The interventions under investigation include: Fludarabine (DRUG), Alemtuzumab (DRUG), Rituximab (DRUG), Thiotepa (DRUG), CD3/CD19 negative hematopoietic stem cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03500731?
This trial is sponsored by Paul Szabolcs, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03500731 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose-Escalation Study of Artesunate Patients With IPF
RECRUITING · Phase 1
-
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
RECRUITING · Phase 1
-
NAL ER IPF Respiratory Function and Safety Study
RECRUITING · Phase 1
-
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 1
-
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
ACTIVE NOT RECRUITING · Phase 1
-
Atezolizumab for Idiopathic Pulmonary Fibrosis
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.